OctoPlus N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 16 apr 2010 - 07:26

Statutaire naam OctoPlus N.V.

Titel Improved tolerability profile Locteron confirmed by data presented at EASL

Bericht OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO) announces that its licensee Biolex Therapeutics has presented yesterday, during the 45th International Liver Congress (EASL) in Austria, a late-breaker poster containing interim clinical results after 12 weeks of treatment with Locteron® from its EMPOWER Phase IIb clinical study.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201004160000000001_Improved tolerability profile of Locteron confirmed by data presented at EASL conference.pdf (opens in a new window)

Datum laatste update: 13 augustus 2025